Discovering therapeutic antibodies designed by nature


For the purpose of therapeutic antibody discovery, the AIMSelect™ platform introduces two genes (Bcl­6 and Bcl-xL) into memory B cells to prevent differentiation and apoptosis. These immortalized B cells

  • are highly stable
  • proliferate rapidly
  • express surface immunoglobulin
  • secrete useful quantities of antibody and
  • can be frozen and thawed without loss of antibody producing capacity

These characteristics make it possible to select relevant monoclonal antibodies among a plethora of antibodies produced by the immortalized cells. Selection can be conducted by binding a labeled antigen to the surface immunoglobulin or by measuring the specific antibody functional activity (i.e., binding, neutralization).